NCT04129099Unknown早期 1 期
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Hebei Yanda Ludaopei Hospital1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2019年10月22日最近更新:
适应症
试验速览
- 阶段
- 早期 1 期
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Incidence and severity of treatment related Adverse Events, CRS and Neurotoxicity (Safety and tolerability)
研究概览
简要总结
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 18 subjects to receive GC022F therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 2-70 years;
- •Eastern cooperative oncology group (ECOG) performance status of 0 to 2;
- •Life expectancy≥12 weeks;
- •CD19 and/or CD22 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry;
- •Relapsed or refractory B- ALL: a) Refractory B- ALL: MRD≥0.1% or fail to achieve a CR after 2 cycles of a standard induction chemotherapy regimen or one-line/multi-line salvage chemotherapy; b) Relapsed B- ALL: Relapse after remission for the first time in 12 months or relapse after one-line/multi-line salvage chemotherapy; Relapse is defined as MRD≥0.1% or recurrence of primitive cell in peripheral blood or bone marrow(>5%) after remission; c)Relapse after autologous stem cell transplantation or allogeneic hematopoietic stem cell transplantation; Relapse is defined as above; d)Patients with Philadelphia chromosome positive(Ph+) ALL were eligible if they were intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or had t315i mutation.
- •Did not receive hematopoietic stem cell transplantation≤6 months prior to enrollment;
- •Adequate organ function defined as: a) Creatinine clearance (as estimated by Cockcroft Gault) >60 mL/min; b) Serum ALT/AST <2.5 ULN; c) Total bilirubin <1.5 ULN (subjects with Gilbert's syndrome≤3 ULN); d) Cardiac ejection fraction≥50%, no evidence of clinically significant pericardial effusion as determined by an ECHO; e) No clinically significant pleural effusion; f) Baseline oxygen saturation >92% on room air;
- •Females of reproductive age must be in non-lactation period. Females of childbearing potential must have a negative serum or urine pregnancy test. All subjects must use medical-approved-contraception (such as intrauterine device and contraceptive drugs) during the period of trial and in 2 years after cell transfusion therapy; Males should avoid sperm donation;
- •Venous access can be established, peripheral blood mononuclear cells (PBMC) can be collected in researcher's judgement;
- •The subject agrees to and sign informed consent form, willing and able to comply with the planned visit, research, treatment planning, laboratory and other test procedures.
排除标准
- •Isolated extra-medullary disease relapse;
- •Central nervous system leukemia involved CNS-3;
- •Concomitant malignancy other than cured non-melanoma skin cancer or cervical carcinoma in situ or localized prostate cancer or superficial bladder cancer or ductal carcinoma in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment during the 5 years;
- •Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb positive with HBV DNA copies positive; TPPA;
- •Live vaccine ≤4 weeks prior to enrollment;
- •For Ph+ ALL, TKI therapy ≤1 weeks prior to enrollment;
- •Presence of ≥ grade 2 acute graft-versus-host disease (GVHD, Glucksberg criteria) or extensive chronic GVHD (Seattle criteria) that require treatment ≤4 weeks prior to enrollment, or during the study period the subject is required to receive anti- GCHD therapy in researcher's judgement;
- •Presence of concomitant disease that require systemic steroids or other immune suppressive therapy during the study period in researcher's judgement;
- •Allogeneic cell therapy (such as donor lymphocyte infusion, DLI) ≤4 weeks prior to enrollment;
- •CNS stereotactic radiotherapy ≤4 weeks prior to enrollment;
- •Toxicities related to previous therapy did not relieved to ≤1 grade, except hematological toxicity and alopecia;
- •Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or presence of other intolerant conditions, or severe allergic constitution;
- •Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Hashimoto's thyroiditis, hypothyroidism which can be controlled by thyroid hormone replacement therapy is an exception);
- •For patients that underwent or plan to undergo major surgical operation before CAR-T treatment, surgical operation happened ≤4 weeks prior to enrollment, or did not be fully recovered and clinically stable prior to enrollment, or be anticipated to undergo major surgical operation during the study;
- •Any unstable cardiovascular diseases happened ≤6 months prior to enrollment, including but not limited to, unstable angina, myocardial infarction, heart failure (NYHA grade≥ III grade), severe arrhythmia that require drug interference, cardiac angioplasty/coronary stent implantation/ cardiac bypass surgery ≤6 months prior to enrollment;
- •Presence of central nervous system(CNS) disease or disease history, including epilepsy, cerebral Ischemia/bleeding, dementia, cerebellar disease, any autoimmune diseases that involve CNS;
- •Presence of active infection that require therapy ≤2 weeks prior to apheresis;
- •Any other conditions that researcher think it is inappropriate for the subject to anticipate the trial.
结局指标
主要结局
Incidence and severity of treatment related Adverse Events, CRS and Neurotoxicity (Safety and tolerability)
时间窗: 2 years
Adverse events(AEs) will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except CRS/ICANS )
次要结局
- CAR copies and concentration of GC022F in peripheral blood, bone marrow and CSF (amplification and persistence)(2 years)
- Overall response rate of patients who received GC022F infusion (efficacy)(2 years)
- Concentraiton of anti-GC022F antibody after infusion (humoral immune response)(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
早期 1 期
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHLB-cell Non Hodgkin LymphomaNCT04412174Hebei Yanda Ludaopei Hospital18
Unknown
早期 1 期
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALLB-cell Acute Lymphoblastic LeukemiaNCT03825731Hebei Yanda Ludaopei Hospital20
尚未招募
1 期
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALLB-cell Acute Lymphoblastic LeukemiaNCT04595162Peking University Third Hospital12
已完成
早期 1 期
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALLB-cell Acute Lymphoblastic LeukemiaNCT03825718Hebei Yanda Ludaopei Hospital29
尚未招募
1 期
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)NCT06641453Chinese PLA General Hospital30